Peptides

Evidence overview

GHK-Cu

GHK-Cu is a copper tripeptide most heavily researched for topical skin applications (cosmetic dermatology, wound healing, hair growth). The systemic-supplementation literature - oral or injected GHK-Cu - is small and emerging. Topical evidence is more developed than systemic evidence, which is the most-practical framing for consumers considering the compound.

Or browse all supplements

Most studied for

Weight management

1 studies

PubMed coverage

2 studies

Across all indexed goals

Safety profile

Preliminary

Strength of safety evidence

Mechanism class

Naturally-occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine. Bound to copper,...

Study coverage

Study coverage by goal

PubMed counts for GHK-Cu grouped by the goal each study targets.

ghk-cu2 studies on PubMed
Your report covers:Body Composition & Metabolic Effects · Appetite, Satiety & Metabolic Health Markers · Dosage & Protocol · Safety

Evidence

What the evidence covers

What's been studied. Conclusions live in the full report.

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally-occurring copper-binding tripeptide found in human plasma, saliva, and urine. The published research base concentrates heavily on topical applications: skin remodeling and cosmetic dermatology (firmness, photoaging, fine lines), wound healing in clinical contexts, hair growth (where the compound is included in some over-the-counter and prescription-adjacent hair-loss products), and burn and scar management. The systemic-supplementation literature - oral GHK-Cu or injectable GHK-Cu - is substantially smaller and more recent. Most consumer marketing for systemic use extrapolates from topical-skin and preclinical evidence.

The outcome dimensions covered most heavily in the topical literature are cosmetic skin outcomes (firmness, hydration, fine lines), wound healing in clinical and post-surgical contexts, and hair regrowth in androgenetic alopecia. Topical GHK-Cu is included in some cosmetic and dermatologic product lines and has cleared the regulatory bar for cosmetic use in many jurisdictions. The much smaller systemic-use literature covers extrapolated tendon and connective tissue applications, hair growth (oral and injectable), and broader anti-aging hypotheses, generally without the systematic-review or expert-society synthesis that would support standard consumer-supplement claims.

The defining feature of the GHK-Cu literature for systemic supplementation is the gap between topical evidence (more developed) and oral/injectable evidence (substantially smaller). Most systemic-use claims rest on extrapolation from topical and preclinical findings. Route of administration matters substantially: topical application acts locally on skin and follicle tissue, while systemic (oral or injectable) administration would have to address absorption, distribution, and metabolism in ways that the available research has not characterized in depth. Product quality and purity vary substantially across sources, particularly for injectable forms typically sold via compounding pharmacies.

Safety

Safety summary

Common adverse events, drug interactions, and special populations.

Topical GHK-Cu has a generally clean safety profile across cosmetic and dermatologic use. The most-common topical adverse effects are mild skin irritation, redness, and (rarely) allergic contact dermatitis. Systemic-supplementation safety is much less well-characterized: oral and injectable use have not been subject to the systematic safety evaluation that topical products in regulated cosmetic and pharmaceutical markets undergo. Excess copper intake is a theoretical concern with systemic supplementation, given the supplement delivers a copper-bound peptide and chronic high copper intake can cause adverse effects including gastrointestinal symptoms and (rarely) hepatic effects. People considering systemic (oral or injectable) GHK-Cu should be aware of the limited safety data and consult a clinician.

This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.

Limitations

What this page doesn't answer

Where the public summary stops and the full report begins.

This page summarizes the GHK-Cu literature at a general level. The most-important limitation is the structural gap between topical evidence (more developed) and systemic evidence (substantially smaller): most consumer marketing for oral or injectable GHK-Cu extrapolates from topical and preclinical data. It does not address route selection (topical vs. oral vs. injectable, with very different evidence bases and use cases), product quality (which varies substantially), what dose has any meaningful clinical support, or how GHK-Cu fits with your specific situation. The personalized report cannot provide firm recommendations for systemic GHK-Cu because the underlying evidence base is not yet sufficient to support them - particularly when topical alternatives have stronger evidence for many of the same outcomes.

Label to evidence

More than GHK-Cu on the label?

Photograph the Supplement Facts panel and Veraflux reads every ingredient printed on it, including the ones a proprietary blend lists without doses, then pulls the published research on each. A free account includes 15 ingredient briefs a month, enough for a full label.

Goal-specific evidence

Get the full GHK-Cu report

Your free monthly report adds the things this page doesn't: per-goal evidence breakdown, full citation list, and a safety section covering all adults, opening with a short plain-language summary so you can orient in seconds before drilling in. On Starter, the report is written for your age and sex too.

A free report every month. No credit card. Cancel anytime.

Get notified when new evidence appears

We'll email you when the literature on GHK-Cu materially updates. No account required.

The human-verification check could not load, possibly because of a browser extension. You can still submit; if it does not go through, try disabling your blocker for this page.